Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest
Phase 3positivezipalertinibPositive
AI Analysis
Summary
Taiho Oncology and Cullinan Therapeutics announced that their oral EGFR inhibitor zipalertinib has successfully cleared a registrational Phase 3 trial in front-line lung cancer with a genetically-defined mutation. The positive data positions the drug to compete with established therapies like Rybrevant.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Registrational Phase 3 trial cleared in front-line setting
Importance:8/10
Sentiment:
0.85
Phase 3lung cancerEGFR inhibitorregistrational trialpositive data
Read the original article
Published by Endpoints News on August 13, 2026 11:11 AM